Stay updated with breaking news from Cellectis daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Performance NASDAQ CLLS opened at $2.71 on Wednesday. The stock has a 50-day simple moving average of $2.77 and a 200 day simple moving […] ....
Investment analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock. Cellectis Stock Performance Shares of Cellectis stock opened at $2.78 on Wednesday. The company has a quick ratio […] ....
Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance Shares of CLLS opened at $3.04 on Monday. The firm has a market cap of $168.96 million, a price-to-earnings ratio of -1.77 and a […] ....
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.